Clinical Outcomes After Palbociclib with or Without Endocrine Therapy in Postmenopausal Women with Hormone Receptor Positive and HER2-negative Metastatic Breast Cancer Enrolled in the TREnd Trial

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2019 May 31

PMID 31142370

Citations 12

Authors

Lorenzo Rossi

Chiara Biagioni

Amelia McCartney

Ilenia Migliaccio

Giuseppe Curigliano

Giuseppina Sanna

Erica Moretti

Alessandro M Minisini

Saverio Cinieri

Carlo Tondini

Grazia Arpino

Antonio Bernardo

Angelo Martignetti

Emanuela Risi

Marta Pestrin

Luca Boni

Matteo Benelli

Laura Biganzoli

Angelo Di Leo

Luca Malorni

Affiliations

Soon will be listed here.

Abstract

Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers.

Citing Articles

Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.

Zhao M, Hanson K, Zhang Y, Zhou A, Cha-Silva A Target Oncol. 2023; 18(3):327-358.

PMID: 37074594 PMC: 10191980. DOI: 10.1007/s11523-023-00957-7.

Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer.

Mittal A, Valiente C, Tamimi F, Schlam I, Sammons S, Tolaney S Cancers (Basel). 2023; 15(7).

PMID: 37046675 PMC: 10093251. DOI: 10.3390/cancers15072015.

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story.

Cogliati V, Capici S, Pepe F, di Mauro P, Riva F, Cicchiello F Life (Basel). 2022; 12(3).

PMID: 35330128 PMC: 8954717. DOI: 10.3390/life12030378.

Single-Cell Proteomic Profiling Identifies Nanoparticle Enhanced Therapy for Triple Negative Breast Cancer Stem Cells.

Wang W, Lei B, Li L, Liu J, Li Z, Pang Y Cells. 2021; 10(11).

PMID: 34831064 PMC: 8616083. DOI: 10.3390/cells10112842.

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.

Scheidemann E, Shajahan-Haq A Int J Mol Sci. 2021; 22(22).

PMID: 34830174 PMC: 8625090. DOI: 10.3390/ijms222212292.

References

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R . ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015; 12(10):573-83. PMC: 4911210. DOI: 10.1038/nrclinonc.2015.117. View

Blum J, Jones S, Buzdar A, LoRusso P, Kuter I, Vogel C . Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999; 17(2):485-93. DOI: 10.1200/JCO.1999.17.2.485. View

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M . Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008; 26(10):1664-70. DOI: 10.1200/JCO.2007.13.5822. View

Dickler M, Tolaney S, Rugo H, Cortes J, Dieras V, Patt D . MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer. Clin Cancer Res. 2017; 23(17):5218-5224. PMC: 5581697. DOI: 10.1158/1078-0432.CCR-17-0754. View

Malorni L, Curigliano G, Minisini A, Cinieri S, Tondini C, DHollander K . Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol. 2018; 29(8):1748-1754. PMC: 6454527. DOI: 10.1093/annonc/mdy214. View

Cristofanilli M, Turner N, Bondarenko I, Ro J, Im S, Masuda N . Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre,.... Lancet Oncol. 2016; 17(4):425-439. DOI: 10.1016/S1470-2045(15)00613-0. View

OShaughnessy J, Petrakova K, Sonke G, Conte P, Arteaga C, Cameron D . Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2017; 168(1):127-134. PMC: 5847028. DOI: 10.1007/s10549-017-4518-8. View

Rugo H, Dieras V, Gelmon K, Finn R, Slamon D, Martin M . Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018; 29(4):888-894. PMC: 5913649. DOI: 10.1093/annonc/mdy012. View

Slamon D, Neven P, Chia S, Fasching P, De Laurentiis M, Im S . Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018; 36(24):2465-2472. DOI: 10.1200/JCO.2018.78.9909. View

10.

Goetz M, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J . MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017; 35(32):3638-3646. DOI: 10.1200/JCO.2017.75.6155. View

11.

Finn R, Dering J, Conklin D, Kalous O, Cohen D, Desai A . PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009; 11(5):R77. PMC: 2790859. DOI: 10.1186/bcr2419. View

12.

Turner N, Slamon D, Ro J, Bondarenko I, Im S, Masuda N . Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018; 379(20):1926-1936. DOI: 10.1056/NEJMoa1810527. View

13.

Finn R, Crown J, Ettl J, Schmidt M, Bondarenko I, Lang I . Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016; 18(1):67. PMC: 4924326. DOI: 10.1186/s13058-016-0721-5. View

14.

Sledge Jr G, Toi M, Neven P, Sohn J, Inoue K, Pivot X . MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017; 35(25):2875-2884. DOI: 10.1200/JCO.2017.73.7585. View